EE9800136A - Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine - Google Patents

Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine

Info

Publication number
EE9800136A
EE9800136A EE9800136A EE9800136A EE9800136A EE 9800136 A EE9800136 A EE 9800136A EE 9800136 A EE9800136 A EE 9800136A EE 9800136 A EE9800136 A EE 9800136A EE 9800136 A EE9800136 A EE 9800136A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
composition suitable
depot
medicine
Prior art date
Application number
EE9800136A
Other languages
English (en)
Other versions
EE03594B1 (et
Inventor
Karel Jozef Fran�ois Marc
Carolus Augusta Embrechts Roger
Karel Borghijs Herman
Monbaliu Johan
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9800136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9800136A publication Critical patent/EE9800136A/et
Publication of EE03594B1 publication Critical patent/EE03594B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EE9800136A 1996-05-20 1997-05-12 Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine EE03594B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
EE9800136A true EE9800136A (et) 1998-10-15
EE03594B1 EE03594B1 (et) 2002-02-15

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800136A EE03594B1 (et) 1996-05-20 1997-05-12 Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine

Country Status (37)

Country Link
US (1) US6077843A (et)
EP (1) EP0904081B1 (et)
JP (1) JP3274687B2 (et)
KR (1) KR100358373B1 (et)
CN (1) CN1093762C (et)
AR (1) AR007194A1 (et)
AT (1) ATE208619T1 (et)
AU (1) AU715572B2 (et)
BG (1) BG62684B1 (et)
BR (1) BR9706824B8 (et)
CA (1) CA2236691C (et)
CY (2) CY2270B1 (et)
CZ (1) CZ291284B6 (et)
DE (2) DE122011100027I1 (et)
DK (1) DK0904081T3 (et)
EA (1) EA000536B1 (et)
EE (1) EE03594B1 (et)
ES (1) ES2167745T3 (et)
FR (1) FR11C0035I2 (et)
HR (1) HRP970276B1 (et)
HU (2) HU224025B1 (et)
ID (1) ID16927A (et)
IL (1) IL124551A (et)
LU (1) LU91842I2 (et)
MX (1) MX9804816A (et)
MY (1) MY126302A (et)
NO (2) NO315931B1 (et)
NZ (1) NZ330369A (et)
PL (1) PL188309B1 (et)
PT (1) PT904081E (et)
SI (1) SI0904081T1 (et)
SK (1) SK284013B6 (et)
TR (1) TR199800923T2 (et)
TW (1) TW487572B (et)
UA (1) UA61898C2 (et)
WO (1) WO1997044039A1 (et)
ZA (1) ZA974331B (et)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69917000T2 (de) * 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
ES2255490T3 (es) 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100818875B1 (ko) * 2000-08-14 2008-04-01 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (ko) * 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
JP5315336B2 (ja) * 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
BRPI0821408A2 (pt) * 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (en) * 2011-05-31 2016-05-25 Ramamohan Rao, Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
IL303254A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
IL303253A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2474701C (en) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
DK0833820T3 (da) * 1995-06-06 2001-04-17 Aventis Pharma Inc Benzisoxazol- og indazolderivater som antipsykotiske midler
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
HUS1100013I1 (hu) 2017-03-28
FR11C0035I1 (et) 2011-07-10
DE69708284T2 (de) 2002-07-25
HK1017852A1 (en) 1999-12-03
PL327995A1 (en) 1999-01-04
JP2000513718A (ja) 2000-10-17
HU224025B1 (hu) 2005-05-30
NZ330369A (en) 2000-04-28
US6077843A (en) 2000-06-20
ZA974331B (en) 1998-11-19
KR100358373B1 (ko) 2003-02-11
EP0904081A1 (en) 1999-03-31
NO2011015I1 (no) 2011-09-19
EA199800531A1 (ru) 1998-12-24
NO981984L (no) 1998-11-19
BR9706824B8 (pt) 2015-02-18
HUP9901319A3 (en) 1999-11-29
SK284013B6 (sk) 2004-08-03
SI0904081T1 (en) 2002-04-30
NO2011015I2 (no) 2013-03-11
DE122011100027I1 (de) 2011-11-17
PL188309B1 (pl) 2005-01-31
CY2270B1 (en) 2003-07-04
HRP970276B1 (en) 2002-04-30
EP0904081B1 (en) 2001-11-14
MY126302A (en) 2006-09-29
CN1206347A (zh) 1999-01-27
IL124551A (en) 2001-08-26
EE03594B1 (et) 2002-02-15
HUP9901319A2 (hu) 1999-08-30
LU91842I2 (fr) 2011-09-20
AR007194A1 (es) 1999-10-13
CA2236691A1 (en) 1997-11-27
FR11C0035I2 (fr) 2013-08-16
NO981984D0 (no) 1998-04-30
KR19990067603A (ko) 1999-08-25
PT904081E (pt) 2002-04-29
DK0904081T3 (da) 2002-02-25
NO315931B1 (no) 2003-11-17
BG102443A (en) 1999-06-30
ES2167745T3 (es) 2002-05-16
HRP970276A2 (en) 1998-04-30
WO1997044039A1 (en) 1997-11-27
CZ140198A3 (cs) 1999-04-14
CZ291284B6 (cs) 2003-01-15
TR199800923T2 (xx) 1999-09-21
ID16927A (id) 1997-11-20
SK62098A3 (en) 2000-04-10
CN1093762C (zh) 2002-11-06
BG62684B1 (bg) 2000-05-31
EA000536B1 (ru) 1999-10-28
DE69708284D1 (de) 2001-12-20
BR9706824A (pt) 1999-03-23
AU715572B2 (en) 2000-02-03
CA2236691C (en) 2007-01-02
AU2955997A (en) 1997-12-09
MX9804816A (es) 1998-10-31
CY2011011I2 (el) 2016-12-14
ATE208619T1 (de) 2001-11-15
JP3274687B2 (ja) 2002-04-15
TW487572B (en) 2002-05-21
UA61898C2 (en) 2003-12-15
IL124551A0 (en) 1998-12-06
CY2011011I1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE9800437A (et) N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks
EE03380B1 (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
FI951468L (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
EE9800180A (et) Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE9800181A (et) Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE9700363A (et) Uus anesteseeriva toimega farmatseutiline segu
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
FI931499A7 (fi) Syklopeptidit, menetelmä niiden valmistamiseksi ja niiden käyttö lääke aineina
FI971861A7 (fi) Puristuskoostumus, valmistusmenetelmä, puristusmenetelmä ja puristustu otteita
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
FI941836A7 (fi) 3-deoksioligosakkaridit, menetelmiä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: XEPLION - PALIPERIDOON; REG NO/DATE: C(2011)1604 04.03.2011

Spc suppl protection certif: C20110009

Filing date: 20110725

FG1Y Spc granted

Free format text: PRODUCT NAME: XEPLION - PALIPERIDOON; REG NO/DATE: C(2011)1604 04.03.2011

Spc suppl protection certif: C20110009 00042

Filing date: 20110725

Extension date: 20220512